DBV TechnologiesDBVT -4.17%31 Debt-to-Equity is 0.03 as of Mar. 2026, which is 50% below its 10-year median of 0.06. GuruFocus rates DBVT with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 964 Biotechnology companies, DBV Technologies ranks better than 81.33% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for DBV Technologies's Debt-to-Equity or its related term are showing as below:
DBVT'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.06 Max: 2.52
Current: 0.03
During the past 13 years, the highest Debt-to-Equity Ratio of DBV Technologies was 2.52. The lowest was 0.02. And the median was 0.06.
DBVT's Debt-to-Equity is ranked better than 81.33% of 964
companies
in the Biotechnology industry
Industry Median: 0.16
vs DBVT: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
DBV Technologies Debt-to-Equity Related Terms
DBV Technologies Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for DBV Technologies's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DBVT vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, DBV Technologies's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DBV Technologies Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DBV Technologies's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where DBV Technologies's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DBV Technologies (DBVT) has a Debt-to-Equity of 0.03 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on DBV Technologies and its competitors. This is 50% below median its historical median of 0.06. Over the past decade, DBV Technologies' Debt-to-Equity has ranged from 0.02 to 2.52. According to the industry distribution chart, DBV Technologies ranks #180 out of 964 companies in the Biotechnology industry, placing it in the top 18.7%.
Is DBV Technologies' Debt-to-Equity too high?
DBV Technologies' current Debt-to-Equity of 0.03 is 50% below median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 2.52. The Biotechnology industry median Debt-to-Equity is 0.16. DBV Technologies' value of 0.03 is 81.3% below this industry median. Based on the distribution chart, DBV Technologies ranks #180 out of 964 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, DBV Technologies has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DBV Technologies' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DBV Technologies ranks #180 out of 964 companies for Debt-to-Equity. This places DBV Technologies in the top 19% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. DBV Technologies' value of 0.03 is 81.3% below this benchmark. Historically, DBV Technologies' own Debt-to-Equity has ranged from 0.02 to 2.52 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 0.16, DBV Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DBV Technologies's current Debt-to-Equity of 0.03 is 81.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on DBV Technologies and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DBV Technologies's current Debt-to-Equity is 0.03, which is 50% below median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DBV Technologies stock overvalued right now?
DBV Technologies (DBVT) has a current Debt-to-Equity of 0.03. The current Debt-to-Equity is 0.03, which is 50% below median its 10-year median of 0.06 and 81.3% below the Biotechnology industry median of 0.16. DBV Technologies' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For DBV Technologies (DBVT), the current Debt-to-Equity is 0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
31GF Score
Get the complete analysis for DBVT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DBVT has been successfully added to your 
